Home / VEGFR2/KDR/Flk-1 / Human VEGFR2/KDR Quantikine ELISA Kit

Human VEGFR2/KDR Quantikine ELISA Kit

Catalog #: DVR200
37 Citations 2 Reviews Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
SVR200
PDVR200
DVR200
Control Products Available
QC05: Quantikine Immunoassay Control Group 2
Human VEGF R2/KDR/Flk-1 ELISA Standard Curve
2 Images
Product Details
Procedure
Citations (37)
FAQs
Supplemental Products
Reviews (2)
Summary Recovery Linearity Data Examples Product Datasheets Preparation and Storage Background Related Research Areas

Human VEGFR2/KDR Quantikine ELISA Kit Summary

Assay Type
Solid Phase Sandwich ELISA
Format
96-well strip plate
Assay Length
4.5 hours
Sample Type & Volume Required Per Well
Cell Culture Supernates (100 uL), Cell Lysates (100 uL), Serum (20 uL), EDTA Plasma (20 uL), Heparin Plasma (20 uL)
Sensitivity
11.4 pg/mL
Assay Range
78.1 - 5,000 pg/mL (Cell Culture Supernates, Cell Lysates, Serum, EDTA Plasma, Heparin Plasma)
Specificity
Natural and recombinant human VEGF R2
Cross-reactivity
< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
Interference
Interference observed with 1 or more available related molecules.

Product Summary

The Quantikine Human VEGF R2 Immunoassay is a 4.5 hour solid-phase Immunoassay designed to measure human soluble VEGF R2 in cell culture supernates, cell lysates, serum, and plasma. It contains NS0-expressed recombinant human VEGF R2/Fc Chimera and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human VEGF R2 showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human soluble VEGF R2.

Recovery

The recovery of VEGF R2 spiked to levels throughout the range of the assay was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 99 92-104

Linearity

To assess the linearity of the assay, samples containing high concentrations of VEGF R2 were serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human VEGF R2/KDR/Flk-1 ELISA Linearity

Scientific Data

N/A Human VEGF R2/KDR/Flk-1 ELISA Standard Curve View Larger

Human VEGF R2/KDR/Flk-1 ELISA Standard Curve

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Preparation and Storage

Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: VEGFR2/KDR/Flk-1

VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

Long Name:
Vascular Endothelial Growth Factor Receptor 2
Entrez Gene IDs:
3791 (Human); 16542 (Mouse)
Alternate Names:
CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2
&#9888; WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Assay Procedure

Refer to the product for complete assay procedure.

Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
  1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
  2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
    3. 100 µL Assay Diluent
  3.   Add 100 µL of Assay Diluent to each well.
    4. 100 µL Standard, Control, or Sample
  4.   Add 100 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours.
  5.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.
    6. 200 µL Conjugate
  6.   Add 200 µL of Conjugate to each well. Cover with a new plate sealer, and incubate at room temperature for 2 hours.
  7.   Aspirate and wash 4 times.
    8. 200 µL Substrate Solution
  8.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes. PROTECT FROM LIGHT.
    9. 50 µL Stop Solution
  9.   Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.

Citations for Human VEGFR2/KDR Quantikine ELISA Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

37 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Unraveling the Angiogenic Puzzle: Pre-Treatment sVEGFR1 and sVEGFR2 Levels as Promising Prognostic Indicators in Early-Stage Breast Cancer Patients
    Authors: Zarychta, E;Bielawski, K;Wrzeszcz, K;Rhone, P;Ruszkowska-Ciastek, B;
    International journal of molecular sciences
    Species: Human
    Sample Types: Plasma
  2. Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues
    Authors: V Rosiek, K Janas, B Kos-Kud?a
    Biomedicines, 2023-03-10;11(3):.
    Species: Human
    Sample Types: Serum
  3. Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer
    Authors: L Fornaro, G Musettini, P Orlandi, I Pecora, C Vivaldi, M Banchi, F Salani, E Fini, V Massa, S Catanese, F Cucchiara, M Lencioni, G Masi, E Vasile, G Bocci
    American journal of cancer research, 2022-07-15;12(7):3347-3356.
    Species: Human
    Sample Types: Plasma
  4. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
    Authors: C Jiguet-Jig, S Boissonnea, E Denicolai, V Hein, R Lasseur, J Garcia, S Romain, R Appay, T Graillon, W Mason, AF Carpentier, AA Brandes, L' Ouafik, W Wick, A Baaziz, JP Gigan, RJ Argüello, D Figarella-, O Chinot, E Tabouret
    Acta neuropathologica communications, 2022-01-03;10(1):1.
    Species: Human
    Sample Types: Plasma
  5. Residual alterations of cardiac and endothelial function in patients who recovered from Takotsubo cardiomyopathy
    Authors: L Zilberman, A Zalik, I Fugenfirov, S Shimoni, J George, S Goland
    Clinical cardiology, 2021-05-06;0(0):.
    Species: Human
    Sample Types: Serum
  6. Hyperoxia sensitizes hypoxic HeLa cells to ionizing radiation by downregulating HIF?1&alpha and VEGF expression
    Authors: D Dong, Y Fu, F Chen, J Zhang, H Jia, J Li, H Wang, J Wen
    Mol Med Rep, 2020-11-20;23(1):.
    Species: Human
    Sample Types: Cell Culture Supernates
  7. Matrix Metalloproteinases MMP-2 and MMP-9, Their Inhibitors TIMP-1 and TIMP-2, Vascular Endothelial Growth Factor and sVEGFR-2 as Predictive Markers of Ischemic Retinopathy in Patients with Systemic Sclerosis-Case Series Report
    Authors: A Waszczykow, M Podgórski, M Waszczykow, Z Gerlicz-Ko, P Jurowski
    Int J Mol Sci, 2020-11-18;21(22):.
    Species: Human
    Sample Types: Serum
  8. Divergent Impact of Breast Cancer Laterality on Clinicopathological, Angiogenic, and Hemostatic Profiles: A Potential Role of Tumor Localization in Future Outcomes
    Authors: RC Barbara, R Piotr, B Kornel, Z El?bieta, R Danuta, N Eduardo
    J Clin Med, 2020-06-02;9(6):.
    Species: Human
    Sample Types: Plasma
  9. A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma
    Authors: C Fountzilas, M Gupta, S Lee, S Krishnamur, B Estfan, K Wang, K Attwood, J Wilton, R Bies, W Bshara, R Iyer
    Br. J. Cancer, 2020-02-10;0(0):.
    Species: Human
    Sample Types: Plasma
  10. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma
    Authors: H Takaya, T Namisaki, M Kitade, K Kaji, K Nakanishi, Y Tsuji, N Shimozato, K Moriya, K Seki, Y Sawada, S Saikawa, S Sato, H Kawaratani, T Akahane, R Noguchi, M Matsumoto, H Yoshiji
    BMC Gastroenterol, 2019-10-21;19(1):167.
    Species: Human
    Sample Types: Serum
  11. Anti-angiogenic efficacy in invasive breast carcinoma patients depends on clinicopathological determinants
    Authors: E Zarychta, P Rhone, K Bielawski, M Michalska, D Ro??, B Ruszkowska
    Adv Med Sci, 2019-02-26;64(2):216-223.
    Species: Human
    Sample Types: Plasma
  12. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants
    Authors: J Sánchez Ra, Y Morera Día, M Bequet-Rom, F Hernández-, KH Selman-Hou, A de la Torr, ER Santiesteb, Y Martín Bau, CH Bermúdez B, J de la Torr, JV Gavilondo, M Ayala Avil
    BMC Immunol., 2017-07-26;18(1):39.
    Species: Human
    Sample Types: Serum
  13. Low grade inflammation inhibits VEGF induced HUVECs migration in p53 dependent manner
    Authors: Sushil Panta
    Biochem. Biophys. Res. Commun, 2016-12-18;0(0):.
    Species: Human
    Sample Types: Cell Culture Supernates
  14. Kinetics of circulating endothelial progenitor cells in patients undergoing carotid artery surgery
    Authors: Günay Kalender
    Ther Clin Risk Manag, 2016-12-14;12(0):1841-1847.
    Species: Human
    Sample Types: Plasma
  15. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.
    Authors: Salazar R, Capdevila J, Laquente B, Manzano J, Pericay C, Villacampa M, Lopez C, Losa F, Safont M, Gomez A, Alonso V, Escudero P, Gallego J, Sastre J, Gravalos C, Biondo S, Palacios A, Aranda E
    BMC Cancer, 2015-02-26;15(0):60.
    Species: Human
    Sample Types: Plasma
  16. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
    Authors: Sallinen H, Heikura T, Koponen J, Kosma V, Heinonen S, Yla-Herttuala S, Anttila M
    BMC Cancer, 2014-09-23;14(0):696.
    Species: Human
    Sample Types: Serum
  17. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
    Authors: Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz L, Morosi C, Crippa F, Fare E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud F, Salvioni R, Daidone M, Gianni A, Mariani L
    Br J Cancer, 2013-11-14;110(1):26-33.
    Species: Human
    Sample Types: Plasma
  18. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
    Authors: Briasoulis, Evangelo, Aravantinos, Gerasimo, Kouvatseas, George, Pappas, Periklis, Biziota, Eirini, Sainis, Ioannis, Makatsoris, Thomas, Varthalitis, Ioannis, Xanthakis, Ioannis, Vassias, Antonios, Klouvas, George, Boukovinas, Ioannis, Fountzilas, George, Syrigos, Kostanti, Kalofonos, Haralamb, Samantas, Epaminon
    BMC Cancer, 2013-05-29;13(1):263.
    Species: Human
    Sample Types: Plasma
  19. Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy.
    Authors: Abu El-Asrar, Ahmed M, Nawaz, Mohd Imt, Kangave, Dustan, Mairaj Siddiquei, Mohammed, Geboes, Karel
    J Diabetes Res, 2013-03-10;0(0):539658.
    Species: Human
    Sample Types: Cell Lysates, Vitreous Humor
  20. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
    Authors: Jurgensmeier J, Schmoll H, Robertson J, Brooks L, Taboada M, Morgan S, Wilson D, Hoff P
    Br J Cancer, 2013-02-28;108(6):1316-23.
    Species: Human
    Sample Types: Plasma
  21. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
    Authors: Somlo G, Atzori F, Strauss L, Geese W, Specht J, Gradishar W, Rybicki A, Sy O, Vahdat L, Cortes J
    Clin Cancer Res, 2013-02-12;19(7):1884-93.
    Species: Human
    Sample Types: Plasma
  22. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
    Authors: Widemann B, Kim A, Fox E, Baruchel S, Adamson P, Ingle A, Glade Bender J, Burke M, Weigel B, Stempak D, Balis F, Blaney S
    Clin Cancer Res, 2012-09-07;18(21):6011-22.
    Species: Human
    Sample Types: Plasma
  23. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
    Br. J. Cancer, 2012-07-17;107(4):639-45.
    Species: Human
    Sample Types: Serum
  24. Prognostic significance of angiogenic factors in uterine cervical cancer.
    Authors: Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kummel S
    Anticancer Res., 2011-08-01;31(8):2589-95.
    Species: Human
    Sample Types: Serum
  25. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
    Authors: Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, Lim HY, Kim JS, Lechuga MJ, Lanzalone S, Lin X, Faivre S
    J Transl Med, 2011-07-25;9(0):120.
    Species: Human
    Sample Types: Plasma
  26. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
    Authors: Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM
    Clin. Cancer Res., 2011-06-20;17(15):5113-22.
    Species: Human
    Sample Types: Plasma
  27. Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept.
    Authors: de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, Deangelis L, Camphausen K, Chen A, Yung W, Prados M, Wen PY, Heymach JV
    Clin. Cancer Res., 2011-06-01;17(14):4872-4881.
    Species: Human
    Sample Types: Plasma
  28. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
    Authors: Loupakis F, Cremolini C, Fioravanti A
    Br. J. Cancer, 2011-03-15;104(8):1262-9.
    Species: Human
    Sample Types: Plasma
  29. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
    Authors: Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, Billiot F, Mauguen A, Hill C, Escudier B
    Br. J. Cancer, 2011-03-08;104(7):1144-50.
    Species: Human
    Sample Types: Plasma
  30. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.
    Authors: Konings IR, de Jonge MJ, Burger H
    Br. J. Cancer, 2010-09-07;103(7):987-92.
    Species: Human
    Sample Types: Serum
  31. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
    Authors: Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK
    J. Clin. Oncol., 2009-05-26;27(18):3027-35.
    Species: Human
    Sample Types: Plasma
  32. Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis.
    Authors: Bourlev V, Iljasova N, Adamyan L, Larsson A, Olovsson M
    Fertil. Steril., 2009-03-25;94(1):52-7.
    Species: Human
    Sample Types: Serum
  33. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.
    Authors: Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S
    Mol. Ther., 2008-12-02;17(2):278-84.
    Species: Human
    Sample Types: Plasma
  34. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Authors: Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD
    J. Clin. Oncol., 2008-03-17;26(11):1810-6.
    Species: Human
    Sample Types: Plasma
  35. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    Authors: Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ
    J. Clin. Oncol., 2007-10-20;25(30):4793-9.
    Species: Human
    Sample Types: Plasma
  36. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
    Authors: Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV
    Clin. Cancer Res., 2007-05-01;13(9):2643-50.
    Species: Human
    Sample Types: Plasma
  37. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction.
    Authors: Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D
    Clin. Sci., 2007-01-01;112(1):51-7.
    Species: Human
    Sample Types: Serum

FAQs

No product specific FAQs exist for this product, however you may

View all ELISA FAQs
Loading...

Reviews for Human VEGFR2/KDR Quantikine ELISA Kit

Average Rating: 5 (Based on 2 Reviews)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human VEGFR2/KDR Quantikine ELISA Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human VEGFR2/KDR Quantikine ELISA Kit
By Anonymous on 08/26/2020
Sample Tested: HUVEC human umbilical vein endothelial cells,TeloHAEC
Human VEGF R2/KDR Quantikine ELISA Kit
By Anonymous on 06/23/2017
Sample Tested: Human cell conditioned medium
Human VEGF R2/KDR Quantikine ELISA Kit DVR200